Detalles de la búsqueda
1.
Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus.
Clin Infect Dis
; 60(5): 787-96, 2015 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25472944
2.
Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality.
Clin Infect Dis
; 61 Suppl 2: S87-93, 2015 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26316562
3.
Telavancin for Acute Bacterial Skin and Skin Structure Infections, a Post Hoc Analysis of the Phase 3 ATLAS Trials in Light of the 2013 FDA Guidance.
Antimicrob Agents Chemother
; 59(10): 6170-4, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26248356
4.
Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment.
Eur J Clin Pharmacol
; 71(6): 707-714, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25939708
5.
Variability in telavancin cross-reactivity among vancomycin immunoassays.
Antimicrob Agents Chemother
; 58(12): 7093-7, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25223996
6.
Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival.
Antimicrob Agents Chemother
; 58(4): 2030-7, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24419353
7.
Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus: a retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studies.
BMC Infect Dis
; 14: 183, 2014 Apr 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-24708675
8.
A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study.
BMC Infect Dis
; 14: 289, 2014 May 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-24884578
9.
Impact of telavancin on prothrombin time and activated partial thromboplastin time as determined using point-of-care coagulometers.
J Thromb Thrombolysis
; 38(2): 235-40, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24132401
10.
Population pharmacokinetics of telavancin in healthy subjects and patients with infections.
Antimicrob Agents Chemother
; 56(4): 2067-73, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22252798
11.
TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections.
Antimicrob Agents Chemother
; 56(11): 5476-83, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22869571
12.
Presence of genes encoding panton-valentine leukocidin is not the primary determinant of outcome in patients with hospital-acquired pneumonia due to Staphylococcus aureus.
J Clin Microbiol
; 50(3): 848-56, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22205797
13.
Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections.
J Antimicrob Chemother
; 67(6): 1496-502, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22416054
14.
Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens.
Clin Infect Dis
; 52(1): 31-40, 2011 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21148517
15.
Challenges in the design and conduct of clinical trials for hospital-acquired pneumonia and ventilator-associated pneumonia: an industry perspective.
Clin Infect Dis
; 51 Suppl 1: S4-9, 2010 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20597670
16.
Presence of genes encoding the panton-valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: results of a multinational trial.
J Clin Microbiol
; 47(12): 3952-7, 2009 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-19846653
17.
Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/tazobactam in healthy participants.
J Clin Pharmacol
; 49(7): 816-23, 2009 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-19443680
18.
Telavancin and hydroxy propyl-beta-cyclodextrin clearance during continuous renal replacement therapy: an in vitro study.
Int J Artif Organs
; 32(10): 745-51, 2009 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-19943236
19.
Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled Trials.
Infect Dis Ther
; 8(3): 445-452, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31372837
20.
Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.
Clin Infect Dis
; 46(11): 1683-93, 2008 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18444791